CASE REPORT

Swinging heart caused by diffuse large B-cell lymphoma

Raúl A. Montañez-Valverde1,3,†, Neal Ivan Olarte2,†, Gerardo Zablah2, David Hurtado-de-Mendoza2 and Rosario Colombo4

1Beth Israel Deaconess Medical Center/Harvard Medical School, Cardiovascular Division, Boston, MA, USA, 2University of Miami Miller School of Medicine/Jackson Memorial Hospital, Miami, FL, USA, 3Universidad Nacional Mayor de San Marcos, Lima, Peru, and 4Jackson Memorial Hospital, Cardiovascular Division, Miami, FL, USA

*Correspondence address. 235 Heath Street, Boston, MA 02130, USA. Tel: +1-786-812-2110; E-mail: montanezvalverde@gmail.com

Abstract

Pericardial disease is a common complication of solid tumors and occasionally seen in hematologic malignancies. Pericardial effusion, when it occurs, is usually caused by tumor seeding of the pericardium leading to a serous effusion or by mass effect from mediastinal lymphadenopathy blocking drainage of lymphatic ducts. Pericardial disease from non-Hodgkin’s lymphoma is uncommon and malignant pericardial effusion is even rarer. Here we present a case of a 31-year-old male with diffuse large B-cell lymphoma who developed cardiac tamponade from a malignant pericardial effusion.

INTRODUCTION

Solid tumor metastasis is a leading cause of pericardial effusion [1]. Its presence is indicative of advanced malignancy and portends a poor prognosis [2, 3]. With large effusions (>500 mL), the heart can appear as swinging from the great vessels, like a pendulum, on echocardiogram [1]. Likewise, the swinging heart is a classic, but uncommon, echocardiographic finding of cardiac tamponade [1]. Diffuse large B cell lymphoma (DLBCL) is the most common of the non-Hodgkin’s lymphomas (NHL), which typically presents as a rapidly enlarging mass in the neck, abdomen, or mediastinum [4]. Mediastinal NHL may produce a pericardial effusion, but rarely presents as cardiac tamponade [5]. Herein we report the first case, to our knowledge, of a patient with DLBCL who presented with cardiac tamponade.

CASE REPORT

A 31-year-old male presented to the emergency room for evaluation of progressive cough, dyspnea, pleuritic chest pain and orthopnea, 1 week after diagnosis of DLBCL. Imaging a week ago revealed diffuse lymphadenopathy involving his right neck, right axilla and a right supraclavicular mediastinal mass encircling the right brachiocephalic vein with severe narrowing of the superior vena cava. Also present were bilateral pleural effusions and a moderate-to-large pericardial effusion. Vital signs were normal and physical exam remarkable only for lymphadenopathy at that time, thus no intervention was performed. The patient was discharged with plans to initiate outpatient treatment for his malignancy which he had not yet begun.

Currently, the patient presented with tachycardia, marginal blood pressure with pulsus paradoxus, muffled heart sounds,
and jugular venous distention, but absent facial and upper extremity edema. His white blood cell count at this time was 7900 cells/mL. Imaging revealed the serosal effusions had increased and the mediastinal mass was now encroaching the right atrium. A 12-lead electrocardiogram showed sinus tachycardia and low-voltage QRS with marked beat-to-beat variation (Fig. 1). A transthoracic echocardiogram confirmed the presence of a very large pericardial effusion (Fig. 2), with multiple features of tamponade including right atrial (RA) systolic collapse, inferior vena cava (IVC) plethora, >25% respiratory variation of the mitral valve inflow, and a swinging heart, as shown in Video 1 of supplementary material.

Emergent pericardiocentesis drained 1100 mL of serosanguineous fluid containing 14000 white blood cells/µL that were 100% lymphocytic. Thoracentesis drained 1100 mL of serous fluid containing reactive mesothelial cells without any significant leukocytosis. The pericardial effusion soon recurred requiring pericardial window placement. After two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), the effusion was minimal. However, interval imaging after four cycles of chemotherapy demonstrated the pericardial effusion had again recurred. Echocardiogram demonstrated the effusion was borderline significant for tamponade, although clinically, the patient denied any symptoms. There was no metabolic activity within the fluid per positron emission tomography scan. Seven months after completing six cycles of R-CHOP the patient had only a small residual mediastinal mass and no serosal effusions. He has been lost to follow-up since.

**DISCUSSION**

Malignant pericardial effusions most often occur in the setting of solid tumors [2, 5]. Hematologic malignant pericardial effusions may also occur, most often with Hodgkin’s disease and less commonly with NHL, the incidence of which has been reported to be as low as 0.8% [2]. We presented here the first known reported case of malignant cardiac tamponade secondary to DLBCL.

Malignant pericardial effusion associated with NHL may represent direct malignant infiltration, effusive-constrictive pericarditis secondary to radiation therapy, invasion of the pericardial space with opportunistic pathogens or an inflammatory effusion secondary to chemotherapy [2, 5], as we suspect was the case in our patient after his third effusion recurrence. In two-thirds of cases, pericardial effusion is a benign complication, and not an extension, of malignancy [6]. A lymphocyte-rich effusion may represent a reactive lymphocytosis indistinguishable from malignancy, but this equivocal yield can be overcome by using morphometry with 85% sensitivity and 95% specificity [2]. Combining cytology with flow cytometry may increase diagnostic yield to 100% sensitivity and 94% specificity [2].

Patients with cardiac tamponade may present with Beck’s triad of distant heart sounds, distended neck veins, and hypotension, but combined these signs are only 50% sensitive for tamponade [7]. Pulsus paradoxus, low-voltage QRS, and electrical alternans are also commonly associated with tamponade, yet the individual sensitivities for each are only 82, 56 and 42%, respectively [8]. The gold standard for diagnosing cardiac tamponade remains right heart catheterization. Echocardiography may also be used and findings such as RA systolic collapse, early RV diastolic collapse, or IVC plethora are all at least 90% sensitive for tamponade [5, 8, 9], all of which were present in our patient.

Cardiac tamponade is a life-threatening emergency with an estimated 85% mortality, requiring immediate pericardiocentesis [9]. Malignant pericardial effusions recur frequently and guidelines for treating recurrence are lacking. Surgical pericardial window has long been a standard therapy but requires general anesthesia, which many advanced cancer patients may not tolerate. For those too sick for surgery, treatment options include percutaneous balloon pericardiotomy, subxiphoid pericardiotomy and pericardial sclerosis, all with various success rates of >90% preventing recurrence [5, 9].
pericardial effusion with either systemic chemotherapy or localized radiation has also been attempted, but success is highly dependent on the sensitivity of the underlying malignancy to the treatment modality [4]. The standard therapy for DLBCL is R-CHOP, with excellent 5- and 10-year overall survival rates [4].

Our patient, like the majority of patients with neoplastic pericardial effusion, presented a positive pericardial fluid study for malignancy, which is associated with a worse prognosis [3, 10]. However, after six cycles of R-CHOP the patient demonstrated near-total resolution of his lymphadenopathy, with no pericardial effusion.

CONCLUSION
Malignant cardiac tamponade is a rare complication of NHL, but when present, represents a life-threatening emergency. The many classic signs and symptoms of tamponade are insensitive for diagnosis; thus, clinicians should have a heightened vigilance of any malignancy involving the mediastinum. Any pericardial effusion significant for tamponade requires immediate drainage, yet preventing recurrence is problematic. Many potential options for preventing recurrence exist with variable success rates, but the only potential preventive treatment is to address the underlying malignancy.

SUPPLEMENTARY MATERIAL
Supplementary material is available at Oxford Medical Case Reports online.

ACKNOWLEDGEMENTS
We are thankful to the clinicians and nurses who managed this patient.

CONFLICT OF INTEREST STATEMENT
The authors of this publication have no financial or nonfinancial relationships to disclose.

FUNDING
No funding was received to publish this case report.

ETHICAL APPROVAL
Patient has been lost to follow-up. This report has omitted any potential identifier.

GUARANTOR
Neal Olarte, Raúl A. Montañez-Valverde.

REFERENCES
1. Jung HO. Pericardial effusion and pericardiocentesis: role of echocardiography. Korean Circ J 2012;42:725–34.
2. Das DK. Serous effusions in malignant lymphomas: a review. Diagn Cytopathol 2006;34:335–47.
3. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol 2005;23:5211–6.
4. Freedman A, Friedberg J, Lister A, Rosmarin A, eds. Initial Treatment of Limited Stage Diffuse Large B Cell Lymphoma. Waltham, MA: Uptodate, 2018.
5. Refaat MM, Katz WE. Neoplastic pericardial effusion. Clin Cardiol 2011;34:593–8.
6. Jiang Y, Xie W, Hu K, Sun J, Zhu X, Huang H. An aggressive form of non-Hodgkin’s lymphoma with pleural and abdominal chylous effusions: a case report and review of the literature. Oncol Lett 2013;6:1120–2.
7. Stolz L, Valenzuela J, S itu-LaCasse E, Stolz U, Hawbaker N, Thompson M, et al. Clinical and historical features of emergency department patients with pericardial effusions. World J Emerg Med 2017;8:29–33.
8. Argula RG, Negi SI, Banchs J, Yusuf SW. Role of a 12-lead electrocardiogram in the diagnosis of cardiac tamponade as diagnosed by transthoracic echocardiography in patients with malignant pericardial effusion. Clin Cardiol 2015;38:139–44.
9. Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015;36:2921–64.
10. Jeong TD, Jang S, Park CJ, Chi HS. Prognostic relevance of pericardial effusion in patients with malignant diseases. Korean J Hematol 2012;47:237–8.